Leading provider of respiratory monitoring technology, PMD Solutions, has been selected to join the prestigious NHS Innovation Accelerator Programme.
The NHS also confirmed rapid adoption of PMD’s RespiraSense product to transform the standard of respiratory care in the UK. Hospitals in Portsmouth, Bradford and London are piloting the device as part of the Health Service’s innovation accelerator programme. The announcement demonstrates the traction PMD Solutions has achieved in the UK market.
Currently awaiting FDA clearance, RespiraSense is expected to be ready for sale within the US by mid 2018. It is anticipated that hospitals and urgent care clinics will follow the lead of the NHS, improving the standard of care and creating cost savings through the introduction of a new standard of respiratory monitoring care.
Founded in 2011, PMD Solutions is focused on developing innovative and patient-friendly technologies to support healthcare provider’s early prevention model of patient care. Inspired by the clinical need to measure patients breathing rates, which when amiss are a significant indicator of deterioration, PMD develops innovative medical devices for the monitoring and diagnosis of respiratory conditions.
Irish Government Minister for Trade, Employment, and Business, Pat Breen TD said, “I was extremely impressed by the high levels of innovation I saw when I visited PMD Solutions at Medica 2017. It is great to see an Irish company at the forefront of medical technology advances.”
PMD Solutions operates from Cork, Ireland, a region recognised as one of the largest exporters of medical products in Europe and one of the five global emerging medical device hubs.
Myles Murray, CEO, PMD Solutions sommented, “We have created an innovation that is set to change the face of in-hospital monitoring at a global scale, improve patient outcomes and generate substantial cost savings for healthcare providers. We are a young company with big ambition. The recent NHS programme has allowed us to engage with global leaders and positioned PMD as an international clinical differentiator in the patient monitoring market.”
The product is helping to fulfil the high-growth early-stage medical device company’s vision of creating a new standard of care regarding in-hospital continuous respiratory rate monitoring. Among several clinical applications, the primary focus of the technology addresses the global technological deficit of accurate and continuous respiratory rate monitoring.
Clinical evaluations of RespiraSense throughout Europe and Australia have seen significant results regarding improving patient care and long-term healthcare economic savings. The device has proven to detect patient deterioration up to 12 hours in advance of an adverse patient event, allowing for early intervention and reducing escalations of care and the associated hospital cost.
To read more Medtech stories, sign up for the newsletter.